Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler Sells 58,590 Shares

Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler sold 58,590 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $249.13, for a total transaction of $14,596,526.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

John Oyler also recently made the following trade(s):

• On Monday, March 3rd, John Oyler sold 101,000 shares of Beigene stock. The shares were sold at an average price of $244.30, for a total transaction of $24,674,300.00.

Beigene Stock Down 3.9 %

ONC opened at $247.07 on Friday. Beigene, Ltd. has a 1 year low of $126.97 and a 1 year high of $287.88. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The firm has a market cap of $24.18 billion, a price-to-earnings ratio of -29.98, a PEG ratio of 7.73 and a beta of 0.65.

Beigene (NASDAQ:ONC) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The firm had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. Sell-side analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Macquarie upped their price target on shares of Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and increased their price target for the company from $207.00 to $320.00 in a research note on Monday, March 3rd.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.